Influenza InfectionNoseFlu-KidsNCT06998264
In-depth Analysis of the Immune Responses in the Upper Respiratory Tract of Influenza-infected Children
An observational study of Influenza Infection, run by University Hospital, Geneva at 1 site in Switzerland.
Trial summary
The NoseFlu-Kids project aims at characterizing the immune response in the upper respiratory tract in children aged 2 to 5 with a laboratory-confirmed influenza infection. The immune response during the acute phase of the infection and after recovery will be compared to that of control children with no infection or… Read more about this study
- Who is it for?
- Ages 2 to 5 years
- Conditions the study is for
- Influenza Infection
- How many people
- 40 participants
- Where
- 1 siteSwitzerland
- Study dates
- 4 Mar 2025to Nov 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 5 years
- All sexes
- No healthy volunteers
- Child
Study population: Participants will be recruited among patients hospitalized or visiting the emergencies at the Geneva University Hospitals (HUG).
Who may be able to join
- Aged 2-5 years
- Presenting clinical signs of an influenza-like illness
- Having a concomitant positive laboratory test for influenza.
Who cannot join
- Immunosuppression
- Intubation or under invasive mechanical ventilation
- Co-infection with RSV or SARS-CoV-2
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Switzerland1 site, 1 recruiting
- Recruiting
Geneva University Hospitals
Geneva, 1205
Jennifer Villers, PhD, +41795538886, jennifer.villers@hug.ch
Arnaud L'Huillier, MD
About this study
The NoseFlu-Kids project aims at characterizing the immune response in the upper respiratory tract in children aged 2 to 5 with a laboratory-confirmed influenza infection. The immune response during the acute phase of the infection and after recovery will be compared to that of control children with no infection or vaccinated with the inactivated flu vaccine by the nasal route (recruited as part of a mirror study in Oxford).
The primary objective of this observational study is to quantify the inflammatory response in the nasal cavity and to correlate it with viral load and with clinical parameters. The study also aims to compare the inflammatory response measured in the nose to that measured in the blood.
Participants will have two study visits including a blood draw, several nasal samplings (nasal lining fluid and nasal cells) and a saliva sampling, one within 72 hours of their hospital admission and another one month later. Nasal lining fluid and saliva will be obtained every two or three days until symptoms disappear. During those visits, questions regarding symptoms will be asked.
- Conditions
- Influenza Infection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Flu kids | Patients aged 2-5 years old hospitalized with flu-like symptoms and a laboratory-confirmed influenza infection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Pro-inflammatory cytokine levels in nasal fluid by a multiplex assay
Measured: 1 month
Secondary outcomes (16)
Phenotypes and frequencies of immune in nasal cavity and in blood cells by flow cytometry
Measured: 1 month
Influenza-specific antibody titers in nasal fluid and blood by ELISA or multiplex assay
Measured: 1 month
Influenza virus load by specific quantitative RT-PCR assay in nasal cavity and/or saliva
Measured: 1 month
Levels of blood cytokines by multiplex assay
Measured: 1 month
Clinical outcome measure 1: nature and severity of symptoms
Measured: 1 month
Clinical outcome measure 2: number of days with fever
Measured: 1 month
Clinical outcome measure 3: number of days with oxygen
Measured: 1 month
Clinical outcome measure 4: highest FiO2
Measured: 1 month
Clinical outcome measure 5: secondary bacterial infection
Measured: 1 month
Clinical outcome measure 6: transfer to ICU or IMCU
Measured: 1 month
Clinical outcome measure 7: length of stay in intensive care
Measured: 1 month
Clinical outcome measure 8: intubation or mechanical ventilation
Measured: 1 month
Clinical outcome measure 9: mortality
Measured: 1 month
Clinical outcome measure 10: rehospitalization
Measured: 1 month
Clinical outcome measure 11: medical consultation for a respiratory disease
Measured: 1 month
Clinical outcome measure 12: new prescription of antibiotics or corticosteroids
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 May 2025
- Study start4 Mar 2025
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Influenza InfectionStudies of the same condition, open and under way.
- More trials run by University Hospital, GenevaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 40 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Geneva
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Prof. Arnaud Didierlaurent, University of Geneva, Switzerland
- Investigators
- Arnaud Didierlaurent, PhD, Principal investigator, University of Geneva, SwitzerlandArnaud L'Huillier, MD, Principal investigator, University Hospital, Geneva
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06998264
- Sponsor's protocol ID
- 2024-01409
- Acronym
- NoseFlu-Kids
- Status last verified
- May 2025
- First submitted
- 28 Mar 2025
- Last updated
- 31 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 31 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- In-depth Analysis of the Immune Responses in the Upper Respiratory Tract of Influenza-infected Children
- ClinicalTrials.gov ID
- NCT06998264
- Acronym / sponsor ID
- NoseFlu-Kids / 2024-01409
- Conditions
- Influenza Infection
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 40 participants (estimated)
- Lead sponsor
- University Hospital, GenevaUniversity, hospital or other
- Study start
- 4 Mar 2025 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 31 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The NoseFlu-Kids project aims at characterizing the immune response in the upper respiratory tract in children aged 2 to 5 with a laboratory-confirmed influenza infection. The immune response during the acute phase of the infection and after recovery will be compared to that of control children with no infection or vaccinated with the inactivated flu vaccine by the nasal route (recruited as part of a mirror study in Oxford).
The primary objective of this observational study is to quantify the inflammatory response in the nasal cavity and to correlate it with viral load and with clinical parameters. The study also aims to compare the inflammatory response measured in the nose to that measured in the blood.
Participants will have two study visits including a blood draw, several nasal samplings (nasal lining fluid and nasal cells) and a saliva sampling, one within 72 hours of their hospital admission and another one month later. Nasal lining fluid and saliva will be obtained every two or three days until symptoms disappear. During those visits, questions regarding symptoms will be asked.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Flu kids | – | –Patients aged 2-5 years old hospitalized with flu-like symptoms and a laboratory-confirmed influenza infection |
Who may qualify
- Ages
- 2 to 5 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
- Study population
- Participants will be recruited among patients hospitalized or visiting the emergencies at the Geneva University Hospitals (HUG).
Key inclusion criteria (3 listed)
- Aged 2-5 years
- Presenting clinical signs of an influenza-like illness
- Having a concomitant positive laboratory test for influenza.
Key exclusion criteria (3 listed)
- Immunosuppression
- Intubation or under invasive mechanical ventilation
- Co-infection with RSV or SARS-CoV-2
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Pro-inflammatory cytokine levels in nasal fluid by a multiplex assay
Time frame: 1 month
16 secondary outcomes
Phenotypes and frequencies of immune in nasal cavity and in blood cells by flow cytometry
Time frame: 1 month
Influenza-specific antibody titers in nasal fluid and blood by ELISA or multiplex assay
Time frame: 1 month
Influenza virus load by specific quantitative RT-PCR assay in nasal cavity and/or saliva
Time frame: 1 month
Levels of blood cytokines by multiplex assay
Time frame: 1 month
Clinical outcome measure 1: nature and severity of symptoms
Time frame: 1 month
Clinical outcome measure 2: number of days with fever
Time frame: 1 month
Clinical outcome measure 3: number of days with oxygen
Time frame: 1 month
Clinical outcome measure 4: highest FiO2
Time frame: 1 month
Clinical outcome measure 5: secondary bacterial infection
Time frame: 1 month
Clinical outcome measure 6: transfer to ICU or IMCU
Time frame: 1 month
Clinical outcome measure 7: length of stay in intensive care
Time frame: 1 month
Clinical outcome measure 8: intubation or mechanical ventilation
Time frame: 1 month
Clinical outcome measure 9: mortality
Time frame: 1 month
Clinical outcome measure 10: rehospitalization
Time frame: 1 month
Clinical outcome measure 11: medical consultation for a respiratory disease
Time frame: 1 month
Clinical outcome measure 12: new prescription of antibiotics or corticosteroids
Time frame: 1 month
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 31 May 2025.
Related trials for Influenza Infection
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
RecruitingPhase 2
BPL-1357 Against H1N1 Influenza Virus Challenge
Influenza, Human
Not yet recruitingPhase 1
Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates
Influenza
RecruitingPhase 1
pH1N1 Blinded Challenge Study
Influenza
RecruitingPhase 3
A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Influenza
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Arnaud Didierlaurent, PhD principal investigator
University of Geneva, Switzerland
Arnaud L'Huillier, MD principal investigator
University Hospital, Geneva
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Influenza Infection, run by University Hospital, Geneva at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 31 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jennifer Villers, PhD (+41 79 553 88 86, jennifer.villers@hug.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pro-inflammatory cytokine levels in nasal fluid by a multiplex assay (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 May 2025.